Table 3 Reasons for switching from TDF to TAF
From: Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort
TDF stopping reason | No TDF-toxicity risk (n = 2′331) | TDF-toxicity risk (n = 465) | Total (n = 2′796) |
|---|---|---|---|
Prevention of expected side-effects | 614 (26.3%) | 83 (17.9%) | 697 (24.9%) |
Established kidney toxicity | 147 (6.3%) | 83 (17.9%) | 230 (8.2%) |
Toxicity, other | 124 (5.3%) | 34 (7.3%) | 158 (5.7%) |
Treatment simplification | 223 (9.6%) | 34 (7.3%) | 257 (9.2%) |
Drug-drug interaction | 15 (0.6%) | 3 (0.7%) | 18 (0.6%) |
Patient’s wish | 195 (8.4%) | 48 (10.3%) | 243 (8.7%) |
Physician’s decision | 375 (16.1%) | 88 (18.9%) | 463 (16.6%) |
Other reason, not specified | 581 (24.9%) | 85 (18.3%) | 666 (23.8%) |
Missing | 57 (2.5%) | 7 (1.5%) | 64 (2.3%) |